Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Nitrogen containing other than solely as a nitrogen in an...
Reexamination Certificate
2007-09-18
2007-09-18
Maier, Leigh C. (Department: 1623)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Nitrogen containing other than solely as a nitrogen in an...
C558S257000, C564S191000
Reexamination Certificate
active
10825531
ABSTRACT:
The present invention provides a CETP activity inhibitor comprising as an active ingredient a compound represented by the formula (I):wherein R represents a straight chain or branched alkyl group; a straight chain or branched alkenyl group; a lower haloalkyl group; a substituted or unsubstituted cycloalkyl group; a substituted or unsubstituted cycloalkenyl group; a substituted or unsubstituted cycloalkylalkyl group; a substituted or unsubstituted aryl group, or a substituted or unsubstituted heterocyclic group, X1, X2, X3, and X4may be the same or different and each represents a hydrogen atom, a halogen atom, a lower alkyl group, a lower haloalkyl group; a lower alkoxy group; a cyano group; a nitro group; an acyl group; or an aryl group, Y represents —CO— or —SO2—, and Z represents a hydrogen atom or a mercapto-protecting group, or a prodrug compound, a pharmaceutically acceptable salt, or hydrate or solvate thereof. The compounds represented by the formula (I) can increase HDL and at the same time decrease LDL through selective inhibition of CETP activity and, therefore, is expected to be useful as a new type of a preventive or therapeutic agent for atherosclerosis or hyperlipidemia.
REFERENCES:
patent: 2596755 (1952-05-01), Young et al.
patent: 3072707 (1963-01-01), Pierson et al.
patent: 3228950 (1966-01-01), Renk et al.
patent: 3260695 (1966-07-01), Bata et al.
patent: 3576830 (1971-04-01), Toshitsugu et al.
patent: 3856840 (1974-12-01), O'Brien et al.
patent: 3920444 (1975-11-01), Harrington et al.
patent: 4033756 (1977-07-01), Hoffmann
patent: 4038300 (1977-07-01), Belmares-Sarabia
patent: 4157444 (1979-06-01), Press et al.
patent: 4337357 (1982-06-01), Uematsu et al.
patent: 4740438 (1988-04-01), Krishnamurthy
patent: 4853319 (1989-08-01), Krishnamurthy et al.
patent: 5118583 (1992-06-01), Kondo et al.
patent: 5194539 (1993-03-01), Charmot
patent: 5217859 (1993-06-01), Boettcher et al.
patent: 5219721 (1993-06-01), Klaus et al.
patent: 5350667 (1994-09-01), Singer et al.
patent: 5362620 (1994-11-01), Lamotte et al.
patent: 5405969 (1995-04-01), Wright et al.
patent: 5446207 (1995-08-01), Pomponi et al.
patent: 5504097 (1996-04-01), Malamas et al.
patent: 5534529 (1996-07-01), Yoshida et al.
patent: 5542974 (1996-08-01), Buding
patent: 5556888 (1996-09-01), Koda et al.
patent: 5614550 (1997-03-01), Yoshida et al.
patent: 5654134 (1997-08-01), Morimura et al.
patent: 5698564 (1997-12-01), Katsuyama et al.
patent: 5776951 (1998-07-01), Arrowsmith et al.
patent: 5919807 (1999-07-01), Muller et al.
patent: 5925645 (1999-07-01), Schmidt et al.
patent: 2000631 (1990-04-01), None
patent: 45-11132 (1970-04-01), None
patent: 1-278543 (1989-11-01), None
patent: 1-321432 (1989-12-01), None
patent: 2-23338 (1990-01-01), None
patent: 3-226750 (1991-10-01), None
patent: WO92/03408 (1992-05-01), None
patent: WO92/03412 (1992-05-01), None
patent: WO96/09406 (1996-03-01), None
STN Document No. 125:346011 (1996).
STN Document No. 113:31865 (1990).
STN Document No. 128:187834 (1998).
STN Document No. 128:69934 (1998).
Vippagunta, S. et al “Crystalline Solids” Adv. Drug Deliv. Rev. (2001) vol. 48, pp. 3-26.
Okamoto, H. et al “A cholesteryl ester transfer protein inhibitor . . . ” Nature (2000) vol. 406, pp. 203-207.□□
Shinkai, H. et al “Bis(2-(acylamino)phenyl) disulfides . . . ” J. Med. Chem. vol. 43, pp. 3566-3572.
Okamoto, H. et al “Effect of JTT-705 on cholesteryl ester transfer protein . . . ” Eur. J. Pharmacol. (2003) vol. 466, pp. 147-154.
Antonova et al.,Dokl. Bulg. Akad. Nauk., 46 (1), 71-74 (1993).
Connolly et al.,Biochem. Biophys. Res. Com., 223, 42-47 (1996).
Drozd,Z. Org. Khim., 23 (2), 355-365 (1987).
Egan et al.,Adv. Prostaglandin, Thromboxane, and Leukotriene Res., 11, 151-157 (1983).
Hori et al.,Heterocycles, 9 (10), 1413-1418 (1978).
Nagarajan et al.,Indian J. Chem., 12 (3), 227-235 (1974).
Simov et al.,Khim. Getero. Soed., 9, 1192-1195 (1976).
Maeda Kimiya
Okamoto Hiroshi
Shinkai Hisashi
Japan Tabacco Inc.
Leydig , Voit & Mayer, Ltd.
Maier Leigh C.
LandOfFree
CETP activity inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with CETP activity inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and CETP activity inhibitors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3723237